Search research articles
Contact Us
Filters
Showing results (91-100 of 126) with videos related to
Page
of 13
Sort By:
Nuklearmedizin. Nuclear Medicine
|
August 1, 1997
[Cost minimization analysis for the definitive therapy of hyperthyroidism: comparison of goiter resection with radioiodine therapy]
M Dietlein, L Geckle, T Overbeck, et al.
Nuklearmedizin. Nuclear Medicine
|
June 18, 2004
18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis
M Schmidt, M Schmalenbach, M Jungehülsing, et al.
Nuklearmedizin. Nuclear Medicine
|
September 16, 2005
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives]
K Schomäcker, M Dietlein, R Schnell, et al.
Nuklearmedizin. Nuclear Medicine
|
November 30, 2012
Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study
B Riemann, K Uhrhan, M Dietlein, et al.
Nuclear Medicine Communications
|
March 27, 1999
Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis
M Dietlein, B Krug, W Groth, et al.
Acta Radiologica (Stockholm, Sweden : 1987)
|
October 4, 2000
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods
B Krug, M Dietlein, W Groth, et al.
Nuklearmedizin. Nuclear Medicine
|
August 19, 2004
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)]
M Dietlein, J Dressler, J Farahati, et al.
Nuklearmedizin. Nuclear Medicine
|
December 9, 2004
[Guideline for radioiodine therapy for benign thyroid diseases (version 3)]
M Dietlein, J Dressler, F Grünwald, et al.
Nuklearmedizin. Nuclear Medicine
|
September 12, 2006
Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004
M Schmidt, T Simon, B Hero, et al.
Nuklearmedizin. Nuclear Medicine
|
October 17, 2007
[Guideline for radioiodine therapy for benign thyroid diseases (version 4)]
M Dietlein, J Dressler, F Grünwald, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 126) with videos related to
Sort By:
Page
of 13
Nuklearmedizin. Nuclear Medicine
|
August 1, 1997
[Cost minimization analysis for the definitive therapy of hyperthyroidism: comparison of goiter resection with radioiodine therapy]
M Dietlein, L Geckle, T Overbeck, et al.
Nuklearmedizin. Nuclear Medicine
|
June 18, 2004
18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis
M Schmidt, M Schmalenbach, M Jungehülsing, et al.
Nuklearmedizin. Nuclear Medicine
|
September 16, 2005
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives]
K Schomäcker, M Dietlein, R Schnell, et al.
Nuklearmedizin. Nuclear Medicine
|
November 30, 2012
Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study
B Riemann, K Uhrhan, M Dietlein, et al.
Nuclear Medicine Communications
|
March 27, 1999
Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis
M Dietlein, B Krug, W Groth, et al.
Acta Radiologica (Stockholm, Sweden : 1987)
|
October 4, 2000
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods
B Krug, M Dietlein, W Groth, et al.
Nuklearmedizin. Nuclear Medicine
|
August 19, 2004
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)]
M Dietlein, J Dressler, J Farahati, et al.
Nuklearmedizin. Nuclear Medicine
|
December 9, 2004
[Guideline for radioiodine therapy for benign thyroid diseases (version 3)]
M Dietlein, J Dressler, F Grünwald, et al.
Nuklearmedizin. Nuclear Medicine
|
September 12, 2006
Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004
M Schmidt, T Simon, B Hero, et al.
Nuklearmedizin. Nuclear Medicine
|
October 17, 2007
[Guideline for radioiodine therapy for benign thyroid diseases (version 4)]
M Dietlein, J Dressler, F Grünwald, et al.
Page
of 13